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Local Recurrence Signiﬁcantly Increases the
Risk of Metastatic Uveal Melanoma
The Ophthalmic Oncology Task Force
Purpose: To assess of the effect of local recurrence of uveal melanoma on metastasis using a multicenter
international tumor registry.
Design: Retrospective study using an online tumor registry.
Participants: Patients with uveal melanoma diagnosed between 2001 and 2011.
Methods: A committee was formed to create uveal melanoma patient-speciﬁc data ﬁelds. Ten subspecialty
ophthalmic oncology centers from 4 continents shared data. Patient selection criteria included diagnosis of uveal
melanoma and adequate records to allow tumor staging by American Joint Committee on Cancer (AJCC) criteria
and follow-up for metastatic melanoma.
Main Outcome Measures: Local tumor recurrence and metastatic uveal melanoma.
Results: Of 3809 total entries, 3217 patients with ciliary body and choroidal (CBC) melanoma and 160 with
iris melanoma were evaluated. There was a median follow-up of 3.7 years (95% conﬁdence interval [CI], 3.5e3.8).
One hundred ﬁfty-two patients (4.7%) with CBC melanoma experienced local recurrence, with a cumulative
incidence of 11%. Kaplan-Meier point estimates for remaining free of local recurrence were 99% (95% CI, 99e99)
at 1 year, 93% (95% CI, 92e94) at 5 years, and 89% (95% CI, 86e91) at 10 years. Five- and 10-year metastasis-
free Kaplan-Meier estimates for the recurrence-free group were 87% (95% CI, 86e89) and 82% (95% CI, 79e84),
and those for the local recurrence group were 71% (95% CI, 62e78) and 62% (95% CI, 49e72). The difference
between these 2 groups was statistically signiﬁcant (P < 0.001). Furthermore, local tumor recurrence increased
the risk of metastasis by a hazard ratio (HR) of 6.28 (95% CI, 4.4e8.9; P < 0.001). Local recurrence was detected
up to 9.8 years after treatment. Extrascleral extension also was associated with local recurrence (HR, 3.2; 95% CI,
1.5e6.7; P ¼ 0.003), but higher AJCC T-size category was not (P ¼ 0.63). Five patients (n ¼ 5/161 [3.1%]) with iris
melanoma demonstrated local recurrence and 1 metastasized.
Conclusions: International multicenter data sharing was used to evaluate the effect of local tumor recurrence
on metastatic rate. In that local tumor recurrence was associated with a signiﬁcantly higher risk of systemic
metastasis, effective initial treatment and long-term surveillance of treated uveal melanoma patients is
necessary. Ophthalmology 2016;123:86-91 ª 2016 by the American Academy of Ophthalmology. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Supplemental material is available at www.aaojournal.org.Local tumor control is a primary goal in the treatment of
cancer.1 In 2002, the Collaborative Ocular Melanoma Study
reported that local treatment failure occurred in 10.3% of
Collaborative Ocular Melanoma Study patients who
underwent iodine 125 plaque brachytherapy.2 More recent
studies, including a literature review of 49 articles,
revealed local recurrence rates ranging from 0% to
55.6%.3 Local orbital recurrence rates after enucleation are
poorly documented, but are believed to be less than 1%.4
These data are important, in that local tumor recurrence is
a complication thought to be associated with an increased
risk of uveal metastasis and thus decreased survival.5e8
However, this current assumption that recurrence equals
increased risk is supported by a relatively few, small single-
center studies and 1 multicenter study; all are limited to 70
or fewer patients with local recurrence.6e8
The Ophthalmic Oncology Task Force comprises mem-
bers of the American Joint Committee on Cancer (AJCC)86  2016 by the American Academy of Ophthalmology
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eye cancer specialists from around the world.9 For this
study, 10 centers pooled their uveal melanoma patient data
in an effort to study this disease.10 We ﬁrst used this
database successfully to test the seventh edition AJCC
uveal melanoma staging system.11 In this study, we
analyzed the data to deﬁne the relationships among local
recurrence, extrascleral extension (EXE), and AJCC
tumor size (T size). However, our primary goal was to
investigate the largest collection of uveal melanomas with
local recurrence and the impact of local recurrence on
metastasis-free survival.
Methods
The Ophthalmic Oncology Task Force collaborated to develop an
Internet-based retrospective registry to evaluate uveal melanoma
outcomes. The methods of data collection and security have been.
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The Ophthalmic Oncology Task Force  Uveal Melanoma Recurrence and Metastasisdescribed previously.11 Each participating center obtained local
ethics and institutional review board approval for participation
and entry of patient data into the online database. This study
conforms to the Declaration of Helsinki and the Health Insurance
Portability and Accountability Act of 1996.
Patient Eligibility
Patient eligibility criteria included patients with primary melanoma
of the iris, ciliary body, and choroid consecutively diagnosed and
treated in a 10-year span from April 1, 2001 through April 30,
2011. Primary tumor treatment methods varied by center, with each
type chosen at the discretion of the eye cancer specialists at each
center. These were reported to include, but were not limited to,
brachytherapy, enucleation or local resection (endoresection and
lamellar eye wall resection), transpupillary thermotherapy with and
without adjuvant radiation therapy, and stereotactic radiotherapy.
However, no numerical treatment-related data were required for
this database.
Detection of local tumor recurrence was determined by ultraso-
nography, comparative fundus photography, or inspection and
palpation of the anophthalmic orbit (after enucleation). Local recur-
rence was determined by clinical and imaging studies used at each
individual center. There were no exclusions to type of recurrence.
Therefore, this study represents site-determined global clinical prac-
tice at 10 centers during this decade. Patients were excluded from
analysis if they had metastasis (stage 4 disease) at initial staging.
Recorded outcome measures included local recurrence and
metastasis. There were no limitations on the methods of screening
for metastasis. However, these included abdominal ultrasound
imaging, computed tomography, magnetic resonance imaging, or
combined whole body positron emission tomography and
computed tomography, as was the custom and practice at each
center. Based on the current assumption that there is no current
curative treatment for almost all patients with metastatic uveal
melanoma and the recognized difﬁculties conﬁrming the actual
cause of death, this study deﬁned metastasis to be synonymous
with metastatic death.
Statistical Analysis
Categorical variables were described using frequencies and pro-
portions. Time to local recurrence was measured from the date of
initial staging. Patients who were alive and free of local recurrence
at last follow-up were censored. One hundred thirty patients (4%)Table 1. Summary of Studies Focused on Local Treatment Failure R
Authors
Treatment
Method
Single or
Multicenter
Median Follow-up
(Range), Years P
Jampol et al
(COMS)2
Iodine 125
plaque
Multicenter 5.6 (0e12.8)
Vrabec et al8 Cobalt 60
plaque
Single 4.9 (1.8e10.7; LR group)
Cajoulle et al6 Proton beam Single No LR: 3.93 (0e17.84)
LR: 5.11 (0.22e17.86)
Gragoudas et al7 Proton beam Single 5.2 (n/a)
Present study Varied Multicenter 3.7 (0.1e12.6)
COMS ¼ Collaborative Ocular Melanoma Study; LR ¼ local recurrence; n/a
*cumulative estimate.died without local recurrence. Because the number of competing
risk events (death without local recurrence) was small relative to
the size of the data set, these patients were censored at their date of
death. Standard methods were used for analysis, rather than
implementing competing risks methodology. Kaplan-Meier plots, a
standard Cox proportional hazards model, and the log-rank test for
trend were implemented to test for a trend relationship between
time to local recurrence and T size (based on the AJCC 7th edition
criteria).12 The standard log-rank test was implemented to test for a
relationship between time to local recurrence and EXE.
Time to metastasis was measured from the date of staging until
the date of metastasis; patients who were alive and free of metas-
tasis at last follow-up were censored. Twenty-ﬁve patients died
without metastasis. Because the number of patients in this latter
category was small relative to the size of the data set, these patients
were censored at their date of death rather than treating their death
as a competing risk event. A Kaplan-Meier plot and the log-rank
test were implemented to test for a relationship between time to
metastasis and local recurrence at last follow-up.
The effect of a local recurrence on the risk of metastasis after
staging also was investigated using Cox models, with local
recurrence treated as a time-varying covariate. In the univariate
model, other factors were not taken into account. An unadjusted
(univariate) model and a model adjusted for stage, T-size category,
and ciliary body involvement or EXE grouping were implemented.
Kaplan-Meier plots, a standard Cox proportional hazards model,
and the log-rank test were implemented to test for a relationship
between time to local recurrence and EXE.
In the analysis of time to metastasis after a local recurrence,
only patients who experienced a local recurrence were included.
Patients who experienced metastasis before a local recurrence or
on the same date as local recurrence were included with their time
to metastasis set to 0.00001 years. Those who had no metastasis
and no follow-up after their local recurrence were excluded. The
related estimates are generalizable to all patients who had a local
recurrence. The Kaplan-Meier curves estimate the probability
of being free of metastasis after a local recurrence. The 95%
conﬁdence limits for this sub-analysis were calculated using the
method of Greenwood13 and the complementary log-log
transformation.
The survival package in R software (R Core Team, Vienna,
Austria) version 2.15.1 was used to generate Kaplan-Meier plots;
SAS TS level 1M1 version 9.3 software (SAS Inc, Cary, NC) was
used to perform all other statistical analyses. Statistical signiﬁcance
was set to 0.05.ates of Choroidal Melanoma and Effect on Metastasis or Death
No. of
atients
No. of Patients
with Local
Recurrence
Local Failure
Incidence (%)
Risk of Metastasis
or Death
650 57 10.3* Adjusted risk ratio, 1.5
for LR (P ¼ 0.08)
445 70 15.7 Estimated 5-yr survival:
87% for LR-free, 58%
for LR (P < 0.0001)
1102 61 6.1 Overall survival at 10 years:
83.6% for LR-free, 43.1%
for LR
1922 62 3.2 Relative risk, 4.1 for LR
3217 152 4.7, 11* Hazard ratio, 6.3 for LR
(P < 0.001)
¼ not available.
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Figure 1. A, The cumulative proportion of patients and (B) a table
showing Kaplan-Meier estimates of local recurrence of primary ciliary body
and choroidal melanoma after initial tumor staging and treatment.
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Participating Centers
Ten ophthalmic oncology centers from 8 countries (Argentina,
Canada, Japan, Russia, Spain, Sweden, The Netherlands, and the
United States) in 4 continents (North and South America, Europe,
and Asia) participated in this study.
Patients
Three thousand eight hundred nine patients with uveal melanoma
were entered into the online database and staged according to the 7th
edition of the AJCC system. Of these, 3377 (89%) records were
complete. One hundred eighty-one patient entries were eliminated
because of lack of follow-up and 67 were eliminated because of
initial presentation with stage 4 disease (metastasis). One hundred
eighty-four were removed because of missing or inconsistent key
variables. This included 118 with unknown metastasis status, 35
with unknown EXE status, 11 with unknown ciliary body involve-
ment status, and 128 with incomplete or inconsistent data that pre-
vented being assigned a T-size category or prognostic stage. Some
patient entries were eliminated for more than 1 of the above reasons.
Primary ciliary body and choroidal melanoma was the diagnosis
for 3217 patients, and 160 patients had primary iris melanoma. The
median follow-up from date of initial diagnosis and staging for the
3217 patients was 3.7 years (95% conﬁdence interval [CI],
3.5e3.8; range, 0.1e12.6 years; Table 1).
Ciliary Body and Choroidal Melanoma
Recurrence
One hundred ﬁfty-two patients (4.7%; n ¼ 152/3217) with ciliary
body and choroidal melanoma experienced local recurrence by
their last follow-up. Kaplan-Meier point estimates for remaining
free of local recurrence were 99% (95% CI, 99%e99%) at 1 year,
93% (95% CI, 92%e94%) at 5 years, and 89% (95% CI,
86%e91%) at 10 years after treatment.
Kaplan-Meier estimates of time to local treatment failure are
shown graphically in Figure 1A and numerically in Figure 1B. Five
years after initial tumor staging, an estimated 7.3% of eyes (95% CI,
6.1%e8.7%) exhibited treatment failure, and an estimated 11% of
eyes exhibited treatment failure at 10 years (95% CI, 8.9%e
13.7%). Local recurrence was detected as early as 1 month and as
late as 9.8 years after initial tumor staging (Fig 1B).
Local Recurrence and Metastasis
Kaplan-Meier point estimates at 5 and 10 years after initial tumor
staging show that there is a statistically signiﬁcant difference in
the metastasis-free survival for the recurrence and recurrence-free
groups (P < 0.001). Forty-three of the 152 patients (28.3%) with
local recurrence demonstrated metastasis, compared with 287
(9.4%) of those who were free of recurrence. For the recurrence-
free group, the 5- and 10-year metastasis-free estimates were 87%
(95% CI, 86%e89%) and 82% (95% CI, 79%e84%), whereas
the recurrence group estimates were 71% (95% CI, 62%e78%)
and 62% (95% CI, 49%e72%), respectively (Fig 2). In a
univariate Cox model, local recurrence increased the risk of
metastasis by a hazard ratio (HR) of 6.28 (95% CI, 4.42e8.92).
Thus, failure of local control was shown to be associated with
a statistically signiﬁcant (P < 0.001) increase in metastatic
disease. Multivariate analysis adjusting for AJCC stage, T-size
category, and presence of ciliary body involvement or EXE
Figure 2. Kaplan-Meier metastasis-free probability for 3217 ciliary body
and choroidal melanoma patients with versus without local recurrence
(LR) (P < 0.001).
Figure 3. Kaplan-Meier metastasis-free probability (solid line) and 95%
conﬁdence limits (dashed lines) for 144 ciliary body and choroidal mela-
noma patients with local recurrence. Note the large conﬁdence interval
after year 5 resulting from the small number of patients.
The Ophthalmic Oncology Task Force  Uveal Melanoma Recurrence and Metastasisdemonstrated that local recurrence was still associated with an
increased risk of metastasis (HR, 6.46; 95% CI, 4.52e9.24;
P < 0.001).
Local Recurrence According to American Joint
Committee on Cancer T-Size Category
According to T-size category and using the entire 3217-patient
cohort, 4.6% of patients in size category T1 (51/1115), 5.7% of
patients in size category T2 (64/1128), 4.3% of patients in size
category T3 (34/789), and 1.6% of patients in size category T4
(3/185) had local recurrence. The evidence failed to show a
trend relationship between T-size category and local recurrence
(P ¼ 0.63, log-rank test for trend; Kaplan-Meier estimates did not
show a trend). No HRs from a Cox proportional hazards model
were statistically signiﬁcant (all P ¼ 0.12 and higher).
Extrascleral Extension and Local Recurrence
Of the 152 patients with local recurrence, 7 patients had EXE.
Using the entire cohort of 3217, 12.5% (7/56) with EXE demon-
strated local recurrence as compared with 4.6% (145/3161) without
EXE who demonstrated local recurrence. The HR from a Cox
proportional hazards model indicated that the presence of EXE was
associated with a higher risk of local recurrence (HR, 3.2; 95% CI,
1.5e6.7; P ¼ 0.003).
Time from Local Recurrence to Metastasis
Only patients who experienced a local recurrence (n ¼ 152) were
included in the analysis of time from local recurrence to metastasis.
Of these, 43 patients (28% [43/152]) with local recurrence
demonstrated metastasis. Six (3.9%) had already experienced
metastasis before local recurrence, 9 (5.9%) had metastasis and
local recurrence detected on the same date, 8 (5.3%) had no follow-
up after their local recurrence, and 28 (18.4%) experienced
metastasis after local recurrence. One hundred one patients (66.4%)
had additional follow-up after their local recurrence date and did
not demonstrate metastasis (during that time).
After excluding 8 patients because of a lack of follow-up after
local recurrence, a cohort of 144 was used to evaluate time to
metastasis, with a median follow-up after local recurrence of 2.3
years (95% CI, 1.8e3.0 years). Forty-three of the 144 patients
(29.9%) who had a local recurrence also had a metastasis either
before, at the same time as, or after local recurrence; the
remaining 70.1% of the sample remained free of metastasis by
their last follow-up date. The median time to metastasis was 6.8
years; however, in Figure 3, note this estimate was based on a
small number remaining at risk for local recurrence with a
large 95% CI (95% CI, 6.2eupper limit cannot be calculated).
The longest interval from local recurrence to detection of
metastasis was 9.8 years. Two (1.4%) patients died without
metastasis.
Local Recurrence of Iris Melanoma
Of the 160 patients with iris melanoma, 5 (3.1%) demonstrated
local recurrence by their last follow-up. Of these 5 patients, 2 were
in T-size category T1, and 3 were T2. One experienced metastasis
2 years after local recurrence, 3 had follow-up after their local
recurrence date (6 months, 6 months, and 3 years) and did not
experience metastasis during that time, and 1 had no follow-up
after local recurrence (and no metastasis). Kaplan-Meier point es-
timates (n ¼ 160) for remaining free of local recurrence were 99%
(95% CI, 95%e100%) at 1 year, 95% (95% CI, 88%e98%) at 5
years, and 93% (95% CI, 82%e97%) at 10 years. This subset was
too small for further statistical analysis.Discussion
Our study revealed that local tumor recurrence signiﬁcantly
increases the risk of metastatic melanoma (P < 0.001; HR,
6.28). This is the highest HR reported to date. Previous
single-center studies evaluating posttreatment local recur-
rence also have found an increased risk of metastasis
(Table 1). For example, Gragoudas et al7 found a relative
risk of 4.1 for those with local recurrence (n ¼ 62) after
proton beam irradiation. Vrabec et al8 reported on cobalt
60 plaque brachytherapy (n ¼ 70) and found a statistically
signiﬁcant decrease in the estimated 5-year survival be-
tween their local recurrence-free (87%) and recurrence
(58%) groups. In another single-center study, Caujolle et al689
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after proton beam therapy decreased from 83.6% (in those
without recurrence) to 55% in those with local recurrence
at 10 years. When compared with our relatively large (n ¼
152) multicenter study, we found that patients with local
recurrence fared slightly better, with 71% (5 years) and
62% (10 years) demonstrating metastasis-free survival.
Unlike the aforementioned studies, we analyzed local
tumor recurrence following the standard of care in multiple
international eye cancer centers using their best-
recommended treatment strategies. That is, the study
cohort included patients treated with varying types of pri-
mary tumor treatment and was not limited to a single
treatment method. Thus, local recurrence rates best reﬂect
the standard of care during that decade. This study provides
evidence that local recurrence signiﬁcantly increases the risk
of metastasis despite the type of primary tumor treatment.
Local radiation failure has been attributed to radiation
resistance, misplacement of radioactive plaque, insufﬁcient
radiotherapeutic margins, and eye movement (primarily
during charged-particle beam therapy).5,14 Therefore, our
ﬁndings support the use of methods to improve local control
(e.g., intraoperative ultrasound to evaluate plaque place-
ment, slotted plaque radiotherapy, 2e3-mm radiotherapeutic
margins, adequate tumor dose and eye ﬁxation during
external beam techniques).15e20 Transpupillary thermo-
therapy and resection can be augmented by adjuvant radi-
ation treatment.21e23 Clearly, our ﬁndings suggest that all
uveal melanoma patients be counseled of greater risks for
metastatic disease should their primary tumor treatment fail.
This study does not examine the exact mechanism of
how local recurrence increased the risk of metastasis. In
addition to therapeutic failure, theories include that recurrent
tumors may have physiologic, genetic, or anatomic char-
acteristics that made them more malignant or early to met-
astasize.11,24e28 It also has been proposed that these
biomarkers may contribute both to outcomes of local
recurrence and to metastasis. However, this study was not
designed to analyze these complex genetic or biological
predisposing factors. Rather, it was designed to evaluate the
relationship between local recurrence and the incidence of
metastatic disease. Certainly, those determining the prog-
nostic efﬁcacy of such tumor-speciﬁc biomarkers should
consider failure of local control in their calculations.
In conclusion, the Ophthalmic Oncology Task Force’s
uveal melanoma registry clearly demonstrates that multi-
center, international data sharing can be used to examine
statistically important clinical questions such as the impact
of failure of local control on metastatic risk. This study
revealed that local recurrence of uveal melanoma is asso-
ciated with a statistically signiﬁcant increase in metastasis
and that this subgroup of high-risk patients deserves
increased surveillance for metastatic disease.
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